Differential Immune-Related Microenvironment Determines Programmed Cell Death Protein-1/Programmed Death-Ligand 1 Blockade Efficacy in Patients With Advanced NSCLC

This publication has 55 references indexed in Scilit:

• PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients
  British Journal of Cancer, 2014
• Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy
  Clinical Cancer Research, 2014
• Anti–CTLA-4 therapy broadens the melanoma-reactive CD8 ⁺ T cell response
  Science Translational Medicine, 2014
• Signatures of mutational processes in human cancer
  Nature, 2013
• Oncology Meets Immunology: The Cancer-Immunity Cycle
  Immunity, 2013
• Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer
  Clinical Cancer Research, 2013
• Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
  Science Translational Medicine, 2012
• CTLA4 Blockade Induces Frequent Tumor Infiltration by Activated Lymphocytes Regardless of Clinical Responses in Humans
  Clinical Cancer Research, 2011
• New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
  European Journal of Cancer, 2009
• Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis
  Molecular Immunology, 2008